Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I

On June 12, 2023, MindRank, which focuses on the use of AI to drive the development of new drugs, announced that the phase I clinical trial of its self-developed GLP-1RA small molecule oral drug MDR-001 successfully completed the first subject administration. MDR-001 is for the treatment of indications such as obesity and type 2 diabetes.

Shanghai Medicilon Inc. (Medicilon), as a strategic partner of MindRank, provided MDR-001 with API process development and preparation R&D services to help speed up its research and development.

Medicilon GLP-1 New Drug R&D Services

One-stop support for new drug development and innovation

From "powerful" hypoglycemic drugs to "miracle" weight-loss drugs, the huge market space of GLP-1 is attracting more attention. As a one-stop biopharmaceutical preclinical research and development service platform, Medicilon has already established a presence in the GLP-1 field, and can provide clients with GLP-1 drug discovery, GLP-1 pharmaceutical research (API process development & preparation), GLP-1 pharmacodynamic research, GLP-1 pharmacokinetic evaluation and GLP-1 safety evaluation.

As of the end of May 2023, Medicilon has successfully assisted 7 GLP-1 drugs to be approved for clinical trials, of which 3 GLP-1 drugs were approved by NMPA/FDA at the same time. There was also another GLP-1 drug was approved by the US FDA, China NMPA and Australia TGA. In addition, there are multiple GLP-1 projects are ongoing under schedule. Relying on rich R&D experience and successful cases, Medicilon has won the trust and affirmation of the clients again and again.

Medicilon congratulates the GLP-1RA small molecule oral drug of MindRank successfully completed the administration of the first subject in clinical phase I. It is hoped that in the next clinical practice, GLP-1RA can send good news to both diabetic and obese patients. Medicilon will also actively embrace new technologies to speed up the new drug development process.

此博客中的热门博文

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Shanghai Medicilon Inc.

搜索此博客